A new synthetic protein, TAT-RH, inhibits tumor growth through the regulation of NFκB activity

Dipartimento di Medicina Clinica, Scienze Cardiovascolari ed Immunologiche, Università Federico II, Napoli, Italia.
Molecular Cancer (Impact Factor: 4.26). 11/2009; 8(1):97. DOI: 10.1186/1476-4598-8-97
Source: PubMed


Based on its role in angiogenesis and apoptosis, the inhibition of NFkappaB activity is considered an effective treatment for cancer, hampered by the lack of selective and safe inhibitors. We recently demonstrated that the RH domain of GRK5 (GRK5-RH) inhibits NFkappaB, thus we evaluated its effects on cancer growth.
The role of GRK5-RH on tumor growth was assessed in a human cancer cell line (KAT-4). RH overexpression was induced by adenovirus mediated gene transfer; alternatively we administered a synthetic protein reproducing the RH domain of GRK5 (TAT-RH), actively transported into the cells.
In vitro, adenovirus mediated GRK5-RH overexpression (AdGRK5-NT) in human tumor cells (KAT-4) induces IkappaB accumulation and inhibits NFkappaB transcriptional activity leading to apoptotic events. In BALB/c nude mice harboring KAT-4 induced neoplasias, intra-tumor delivery of AdGRK5-NT reduces in a dose-dependent fashion tumor growth, with the highest doses completely inhibiting it. This phenomenon is paralleled by a decrease of NFkappaB activity, an increase of IkappaB levels and apoptotic events. To move towards a pharmacological setup, we synthesized the TAT-RH protein. In cultured KAT-4 cells, different dosages of TAT-RH reduced cell survival and increased apoptosis. In BALB/c mice, the anti-proliferative effects of TAT-RH appear to be dose-dependent and highest dose completely inhibits tumor growth.
Our data suggest that GRK5-RH inhibition of NFkappaB is a novel and effective anti-tumoral strategy and TAT-RH could be an useful tool in the fighting of cancer.


Available from: Alfonso Campanile
  • Source
    • "As ISA27 exerts the same effect in p53 WT (MCF7) and p53-mutated cells (KAT-4 and BHT-101) and given the hotspot mutation of p53 within the DNA-binding domain in KAT-4 and BHT-101 cells, which inhibits its transcriptional activity (Blagosklonny et al, 1998), the effect of ISA27 in the regulation of apoptosis should be independent from p53 transcriptional activity. We therefore performed the study in KAT-4 cells, which represent a well-established model for cancer studies in our laboratory (Sorriento et al, 2009). We first confirmed the effectiveness of ISA27 to disrupt MDM2/p53 binding in KAT-4 cells by co-immunoprecipitation assay. "
    [Show abstract] [Hide abstract]
    ABSTRACT: p53 is a transcription factor with tumour suppressor properties, which is able to induce mitochondrial apoptosis independently of its transcriptional activity. We recently synthesised two new compounds (ISA27 and SM13), which block p53-MDM2 interaction and induce apoptosis in p53 wild-type (WT) tumour cells. The aim of this study was to verify the effectiveness of these compounds in tumours carrying a mutated form of p53 gene with no transcriptional activity. In vitro we evaluated the effectiveness of our compounds in cancer cell lines carrying WT, mutated and null p53 gene. In vivo study was performed in Balb/c nude mice and the mitochondrial-dependent apoptotic signalling was evaluated by western blot. Both ISA27 and SM13 reduced cell proliferation and induced apoptosis in vitro in cells carrying either p53 WT or mutated gene, suggesting that its effect is independent from p53 transcriptional activity. On the contrary, SM13 had no effect in a p53 null cell line. In vivo, ISA27 and SM13 induced cancer cell death in a dose-dependent manner through the activation of the mitochondrial-dependent death signalling in p53-mutated cells. In vivo, SM13 reduced tumour growth. Our study proposes SM13 as anticancer compound to use for the treatment of p53-dependent tumours, even in the absence of p53 transcriptional activity.
    British Journal of Cancer 01/2015; 112(1):77-85. DOI:10.1038/bjc.2014.577 · 4.84 Impact Factor
  • Source
    • "Methods are as previously described [25] [26] [27] [28] [29] [30] [31] [32] [33]. Extended details are available in Supplements. "
    [Show abstract] [Hide abstract]
    ABSTRACT: G-protein-coupled receptor kinase 2 (GRK2) levels are elevated in inflammation but its role is not clear yet. Here we show that GRK2 expression is dependent on NFκB transcriptional activity. In macrophages, LPS induces GRK2 accumulation in mitochondria increasing biogenesis. The overexpression of the carboxy-terminal domain of GRK2 (βARK-ct), known to displace GRK2 from plasma membranes, induces earlier localization of GRK2 to mitochondria in response to LPS leading to increased mt-DNA transcription and reduced ROS production and cytokine expression. Our study shows the relevance of GRK2 subcellular localization in macrophage biology and its potential therapeutic properties in inflammation.
    FEBS letters 09/2013; 587(21). DOI:10.1016/j.febslet.2013.09.002 · 3.17 Impact Factor
  • Source
    • "In BALB/c nude mice harbouring KAT-4 induced neoplasias, intra-tumour delivery of AdGRK5-NT reduces in a dose-dependent fashion tumour growth, with the highest doses completely inhibiting it. This phenomenon is paralleled by a decrease of NFκB activity, an increase of IκB levels and apoptotic events [27]. To move towards a pharmacological setup, we synthesized the TAT-RH protein. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nuclear factor κB (NFκB) is a transcription factor that plays an important role in carcinogenesis as well as in the regulation of inflammatory response. NFκB is constitutively expressed in tumours where it induces the expression of genes which promote cell proliferation, apoptotic events, angiogenesis, invasion and metastasis. Furthermore, many cancer cells show aberrant or constitutive NFκB activation that mediates resistance to chemo- and radio-therapy. Therefore, the inhibition of NFκB activity appears a potential therapeutic strategy for cancer treatment. In this review, we focus on the role of NFκB in carcinogenesis and summarize actual inhibitors of NFκB that could be potential therapeutic target in cancer therapy.
    09/2012; 4:73-85.
Show more